Background The success of streptokinase in acute myocardial infarction is hampered by the high failure rate to achieve early reperfusion. This study evaluates the possible benefit of Hirulog (Biogen, Cambridge, Mass), a direct thrombin inhibitor, as adjunct therapy to streptokinase to enhance early patency and prevent rethrombosis. Heparin has been shown to be of very limited benefits in this setting.
Methods and Results Forty-five patients were randomized to Hirulog or heparin (2:1 ratio). Coronary angiography documented a TIMI 2 or 3 flow after 90 minutes in 77% of the patients treated with Hirulog and streptokinase and in 47% of patients treated with heparin and streptokinase (P<.05) and after 120 minutes in 87% and 47% of patients, respectively (P<.01). TIMI 3 flow was established in 77% of patients with Hirulog compared with 40% with heparin (P<.02). The clinical outcome and the bleeding rate were also favorable to Hirulog; no reocclusion was observed at late angiography performed 4.7 days later.
Conclusions Hirulog in this pilot study significantly improved the early patency rate of the infarct-related artery with a favorable clinical profile. This new direct thrombin inhibitor exhibits promise as adjunctive therapy to thrombolysis. (Circulation. 1994; 89:1567 -1572 Key Words * angiography * heparin * streptokinase I ntravenous thrombolytic therapy improves ventricular function12 and reduces mortality in acute myocardial infarction.3'4 However, failure to achieve early patency25 and reocclusion after successful reperfusionM occur in many patients despite the use of various thrombolytic regimens. These unwanted events are associated with poorer left ventricular function and a worse prognosis, limiting the benefits of thrombolySiS. 2, 6, 7 Experimental studies, on the other hand, have shown that recombinant hirudin8-11 and related specific thrombin inhibitors such as Hirulog (Biogen, Cambridge, Mass)12"3 could facilitate thrombolysis and prevent rethrombosis better than heparin and antiplatelet therapy when used in combination with tissue plasminogen activator8,10-13 or with streptokinase.9 This study was designed as a pilot study to determine whether Hirulog, a highly specific and potent bivalent inhibitor of thrombin, could be useful as adjunctive therapy to streptokinase to restore coronary blood flow in the infarct-related artery and to maintain patency.
Methods

Inclusion of Patients
Recruitment for this study was done using a fast-track procedure for early identification and management of patients with acute myocardial infarction. Patients admitted for chest pain were rapidly questioned and examined by the on-site medical staff, and a 12-lead ECG was obtained. The indication for thrombolysis, the absence of contraindications, and the eligibility for the study were immediately established. Inclusion criteria were onset of chest pain within the preceding 6 hours and ST segment elevation .1 mm in two contiguous ECG leads.
The presence of any exclusion factors was ruled out using a quick checklist: previous administration of streptokinase, the presence of acute pulmonary edema or shock, a history of hemorrhagic stroke, intracranial bleeding or transient cerebral ischemic attacks, uncontrolled hypertension (>180/110 mmHg), childbearing potential, gastrointestinal bleeding within the previous 2 years, major surgery or trauma within the previous 3 months, arterial puncture in a noncompressible site within the previous month, a known bleeding disorder, or any severe associated disease contraindicating the use of streptokinase. Participation in the study was proposed to eligible patients while the standard monitoring facilities were installed. The study drugs were initiated shortly after obtaining a signed informed consent, and the cardiac catheterization team was notified of patient eligibility. This procedure was operative on a 24-hour-a-day basis including weekends.
Study Drug Administration
The solutions were prepared daily by the hospital pharmacist and kept in a sealed bag at the emergency room. Randomization was double-blind, and the sequence included a ratio of two patients receiving Hirulog for one patient receiving heparin. The rationale for this design was to increase the statistical power for the analysis of the experimental group refusal by two patients and nonavailability of the catheterization laboratory for two others (Table 1) .
A total of 45 patients, 10 women and 35 men with a mean age of 56± +10 years (range, 26 to 77), were included in the study. The clinical characteristics of these patients are listed in Table 2 . Age, sex, blood pressure at admission, and site of the myocardial infarction were the same in the two study groups. Mean time elapsed from onset of pain to start of streptokinase was 149±59 minutes and from onset of streptokinase to coronary angiography, 65±19 minutes, similar in the two study groups. The Hirulog patients were less frequently smokers and more often had experienced a previous infarction.
Early and High blood pressure 4 5 Previous myocardial infarction 6 5 Previous PTCA 19 9 Intravenous p-blocker 14 5 Oral 3-blocker 21 7 Calcium antagonists 14 8 PTCA indicates percutaneous transluminal coronary angioplasty; SK, streptokinase; and Ml, myocardial infarction.
onary angioplasty was performed in 18 patients at the time of late angiography.
Clinical Evolution
The clinical evolution and the bleeding complications are shown in Table 3 
Discussion
This study suggests that Hirulog, one of the new direct thrombin inhibitors, can potentiate the thrombolytic efficacy of streptokinase, resulting in an enhanced rate of early patency of the infarct-related artery. Consecutive patients were randomized to enter the study within 6 hours of the onset of pain. The relative risk for restoring blood flow with Hirulog compared with heparin was 1.86 (95% confidence limits, 1.06 to 3.25) and for restoring TIMI grade 3 flow, 1.92 (95% confidence limits, 1.00 to 3.67). Reocclusion occurred in no Hirulog-treated patients.
Hirulog is a 20-amino-acid, synthetic peptide modeled on hirudin. It binds both to the anion-binding exosite and to the catalytic site of the thrombin molecule. 15 The inhibition is equimolar, direct, and specific. Like hirudin, its use in experimental models of coronary artery thrombosis resulted in accelerated thrombolysis and prevention of rethrombosis.'3 Explanations provided for a better efficacy of the direct thrombin inhibitors have been the absence of endogenous inhibitors", and their ability to inhibit clot-bound thrombin, 7 overcoming two limitations of heparin.
This study was designed as a pilot study, and the small sample size limits the power of all conclusions that can be derived. However, consecutive patients were randomized in a double-blind fashion to Hirulog or heparin. The study end points were objective and quantified in a blinded manner. The baseline characteristics were in general well balanced, with the exception of fewer smokers and more previous myocardial infarctions in the Hirulog group; these two factors are associated with a less favorable clinical outcome after myocardial infarction18'19; nonsmokers also experienced early recurrent infarction more often. ' flow, which is clearly associated with better clinical evolution and left ventricular function,2425 showed a success rate of 40% with heparin; yet, the success rate with Hirulog was 77%, nearly twice as frequent.
The aPTT prolongations achieved with Hirulog and with heparin were above the accepted therapeutic range throughout the study. The higher values observed at 60 and 120 minutes with Hirulog may be explained by the different half-life and distribution volume of Hirulog and heparin with bolus injections given. The values observed with Hirulog in this study were almost twice the values observed at similar doses in a previous study of patients with unstable angina; the plasma levels of the drug were, however, the same. 26 The aPTT values with heparin also were higher than expected and above the usual target therapeutic range. These exaggerated prolongations of the aPTT with both drugs are probablv related to the effects of fibrinolytic therapy, producing a systemic hypocoagulable state. The early difference in aPTT observed between the two drugs probably does not explain the differences in the patency rates. In the angiographic substudy of GUSTO,7 the use of a 5000-U bolus of heparin followed by an infusion of 1000 U per hour resulted in no better patency rate at 90 and 180 minutes than when heparin was started subcutaneously after 4 hours: indeed, TIMI 2 flow at 90 minutes was observed in 28% of patients with the bolus injection and in 25% with the subcutaneous administration and TIMI 3 flow in 32% and 29% of patients, respectively. At 180 minutes, these figures were 33% and 38% for TIMI 2 and 41% and 35% for TIMI 3 flow. These results of GUSTO validate our study design with no intravenous bolus of heparin given. The GUSTO trial showed that the best therapeutic strategy was accelerated recombinant tissue plasminogen activator (rTPA) plus intrave-nous heparin, resulting in TIMI 3 flow in 54% of patients at 90 minutes and in 43% at the 180-minute angiogram. In this study, the combination of Hirulog and of streptokinase resulted in further improvement with TIMI 3 flow in 67% of patients at 90 minutes and in 77% of patients at 120 minutes.
Whether the findings of this study with enhanced thrombolysis with Hirulog added to streptokinase will be reproduced in a larger and more definitive trial and whether they will also apply to the use of other fibrinolytic agents remain to be investigated. The dose of Hirulog selected was based on a previous dose-ranging study in patients with unstable angina observing the anticoagulant and antithrombotic properties of Hirulog; the optimal dose to use as adjunctive therapy to thrombolysis remains to be investigated. A patency rate of approximately 80% could represent as much as can be gotten; it is possible, however, that a better strategy can still improve results. Two abstracts have reported the use of recombinant hirudin as adjunctive therapy to rTPA. In the TIMI-5 study, infarct vessel patency at 90 minutes was 79% with hirudin and 83% with heparin (NS)27; reocclusion or recurrent ischemic pain occurred significantly less frequently with hirudin, however: 8% of patients compared with 18% with heparin. The other report described satisfactory angiographic results with the combination of recombinant hirudin and rTPA in 40 patients and an absence of major bleeding.28 The benefits of a new adjunctive therapy may be more easily documented when streptokinase is used as a fibrinolytic agent, since this drug is associated with delayed reperfusion compared with rTPA. 7 This study lacks sufficient power to evaluate clinical events; these were more frequent than expected in the heparin group because of the small number of patients. However, much evidence now relates a favorable clinical evolution to more complete and earlier restoration of blood flow.722 The large trials have shown that earlier treatment resulted in lower mortality, suggesting that early reperfusion is important.3'4 Many studies have also suggested that early patency was associated with smaller infarcts, better left ventricular function, and reduced morbidity and mortality. 24 The GUSTO trial confirmed this relation by showing that reperfusion achieved 90 minutes after thrombolysis, either with rTPA or with streptokinase, was associated with smaller end-systolic volume, better ejection fraction, and reduced mortality.7 In our study, a composite end point of clinical events showed a favorable profile for Hirulog; the only two events that occurred were congestive heart failure in one patient and death by aortic rupture in another patient who received heparin after failed reperfusion with streptokinase and Hirulog. Bleeding complications were frequent, but most were minor and related to the catheterization procedure. Severe bleeding complications occurred less frequently with Hirulog, and severe systemic bleeding was observed only during heparin therapy. The TIMI-5 study also has shown less bleeding with hirudin combined with rTPA compared with heparin combined with rTPA.27 Heparin has a narrow risk-benefit ratio; both efficacy and risk increase with higher doses.29 Such may not be the case with the new antithrombin drugs. The results of this study suggest enhanced thrombolysis with adjunctive therapy to streptokinase and a favorable clinical profile. These findings, if confirmed in larger trials, could lead to more optimal use of thrombolytic agents, defining a new adjunctive therapy specifically targeted at thrombin inhibition.
